

1 **Polygenic risk scores for asthma and allergic disease associate with COVID-19 severity in**  
2 **9/11 responders**

3  
4 Monika A. Waszczuk, PhD<sup>1</sup>, Olga Morozova, PhD<sup>2</sup>, Elizabeth Lhuillier, MD<sup>3,4</sup>, Anna R.  
5 Docherty, PhD<sup>5,6</sup>, Andrey A. Shabalin, PhD<sup>5,6</sup>, Xiaohua Yang, MS<sup>4</sup>, Melissa A. Carr, Ms<sup>3</sup>, Sean  
6 A. P. Clouston, PhD<sup>7</sup>, Roman Kotov, PhD<sup>8</sup>, and Benjamin J. Luft, MD<sup>3,4</sup>

7  
8 <sup>1</sup> Department of Psychology, Rosalind Franklin University of Medicine and Science, North  
9 Chicago, IL

10 <sup>2</sup> Department of Public Health Sciences, Biological Sciences Division, University of Chicago,  
11 Chicago, IL

12 <sup>3</sup> World Trade Center Health and Wellness Program, Stony Brook University, Stony Brook, NY

13 <sup>4</sup> Department of Medicine, Stony Brook University, Stony Brook, NY

14 <sup>5</sup> Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT

15 <sup>6</sup> Huntsman Mental Health Institute, Salt Lake City, UT

16 <sup>7</sup> Program in Public Health, Department of Family, Population, and Preventive Medicine, Stony  
17 Brook University, Stony Brook, NY

18 <sup>8</sup> Department of Psychiatry, Stony Brook University, Stony Brook, NY

19

20

21 **Corresponding author:**

22 Benjamin J. Luft, MD

23 Email: [Benjamin.Luft@stonybrookmedicine.edu](mailto:Benjamin.Luft@stonybrookmedicine.edu)

24 **ORCID IDs:**

25 Monika A. Waszczuk: 0000-0003-1775-1970

26 Olga Morozova: 0000-0001-7606-8413

27 Anna R. Docherty: 0000-0001-7139-7007

28 Andrey A. Shabalin: 0000-0003-0309-6821

29 Melissa Carr: 0000-0002-0870-6628

30 Roman Kotov: 0000-0001-9569-8381

31 Benjamin J. Luft: 0000-0001-9008-7004

32

33 **Abstract:** 198 words

34 **Manuscript:** 3,514 words

35 **Tables:** 4

36 **References:** 29

37

38

## 39 Abstract

40 **Background.** Genetic factors contribute to individual differences in the severity of coronavirus  
41 disease 2019 (COVID-19). A portion of genetic predisposition can be captured using polygenic  
42 risk scores (PRS). Relatively little is known about the associations between PRS and COVID-19  
43 severity or post-acute COVID-19 in community-dwelling individuals. **Methods.** Participants in  
44 this study were 983 World Trade Center responders infected for the first time with SARS-CoV-2  
45 (mean age at infection=56.06; 93.4% male; 82.7% European ancestry). Seventy-five (7.6%)  
46 responders were in the severe COVID-19 category; 306 (31.1%) reported at least one post-acute  
47 COVID-19 symptom at 4-week follow-up. Analyses were adjusted for population stratification  
48 and demographic covariates. **Findings.** The asthma PRS was associated with severe COVID-19  
49 category (odds ratio [OR]=1.61, 95% confidence interval: 1.17-2.21) and more severe COVID-  
50 19 symptomatology ( $\beta$ =.09,  $p$ =.01), independently of respiratory disease diagnosis. Severe  
51 COVID-19 category was also associated with the allergic disease PRS (OR=1.97, [1.26-3.07])  
52 and the PRS for COVID-19 hospitalization (OR=1.35, [1.01-1.82]). PRS for coronary artery  
53 disease and type II diabetes were not associated with COVID-19 severity. **Conclusion.** Recently  
54 developed polygenic biomarkers for asthma, allergic disease, and COVID-19 hospitalization  
55 capture some of the individual differences in severity and clinical course of COVID-19 illness in  
56 a community population.

57

58 **Keywords:** 9/11 responders; COVID-19; SARS-CoV-2; post-acute COVID-19 syndrome;  
59 polygenic risk score; asthma; allergic disease

60

61 **Polygenic risk scores for asthma and allergic disease associate with COVID-19 severity in**  
62 **9/11 responders**

63 **Introduction**

64 Coronavirus disease 2019 (COVID-19) is caused by an infection by the severe acute respiratory  
65 syndrome coronavirus (SARS-CoV-2) and remains a pandemic in the US and globally [1].  
66 COVID-19 invades the respiratory and other crucial systems in the body, varying widely in  
67 severity, from asymptomatic presentation to severe outcomes including hospitalization or death.  
68 Moreover, at least one-third of individuals with COVID-19 develop post-acute COVID-19  
69 syndrome [2], which consists of residual respiratory, fatigue, central nervous system, and  
70 musculoskeletal symptoms that persist at least four weeks after initial symptom onset [3, 4].  
71 Despite vaccination efforts, the potentially severe and chronic outcomes of COVID-19  
72 necessitate a better characterization of individuals at elevated risk for clinically significant  
73 disease outcomes.

74 Across a range of studies, COVID-19 severity was found to be associated with clinical risk  
75 factors such as older age, male sex, smoking, respiratory illness, cardiovascular disease, and  
76 immunocompromised status [5-7]. Moreover, a person's own genetic factors critically affect  
77 individual differences in COVID-19 disease severity [8]. Large-scale, population-based genome-  
78 wide association studies (GWAS) indicate that multiple common genetic variants can contribute  
79 to COVID-19 symptom severity after infection [9]. Genes that emerged from GWAS most  
80 strongly associated with severe COVID-19 progression are involved in immune response and  
81 lung disease pathology. The individual variants associated with disease severity in the discovery  
82 GWAS have minor effects, but cumulatively they explain a substantial proportion of genetic

83 variation in response to the virus. Common variants can be collapsed into a polygenic risk score  
84 (PRS) to improve the prediction of at-risk patients in an independent cohort. For each individual,  
85 the number of risk alleles carried at each variant (0, 1, or 2) can be summed and weighted by its  
86 effect size, resulting in a single score of each individual's genetic vulnerability to COVID-19  
87 severity.

88 COVID-19 PRS have shown to be associated with increased risk of morbidity and mortality due  
89 to COVID-19 in several independent samples and across ancestries, with PRS outperforming  
90 individual genetic variants and providing information over and above established risk factors  
91 [10-13]. While the COVID-19 PRS was designed to capture all genes associated with the  
92 severity of COVID-19, the studies relied partially on the UK Biobank cohort, which has limited  
93 phenotypic information on COVID-19 disease and exposure status of controls, largely based on  
94 electronic medical records of laboratory test results and ICD-10 codes for COVID-19 and  
95 respiratory support. It is therefore plausible that other PRS capture genetic vulnerability to other  
96 conditions, such as asthma or coronary artery disease, that might also associate with COVID-19  
97 symptom severity or COVID-19 clinical course, although empirical evidence is limited. For  
98 example, only one published study has reported no association between asthma PRS and severe  
99 COVID-19 [14], but no other studies to our knowledge have examined post-acute COVID-19  
100 symptoms.

101 Therefore, the present study translated genetic discoveries in COVID-19 host genetics to an  
102 independent, well-characterized patient population with a full range of COVID-19 severity.  
103 Responders to the World Trade Center (WTC) attacks on September 11, 2001 are a cohort with  
104 detailed prospective health data, including information on COVID-19 infection, symptom  
105 severity, and follow-up outcomes. Our team has previously demonstrated that younger and

106 employed responders were at a higher risk of being infected with the SARS-CoV-2 virus [15].  
107 Among those who experienced infection, a pre-existing obstructive airway disease diagnosis  
108 predicted an elevated risk for a more severe COVID-19 presentation [2]. The risk of developing  
109 post-acute COVID-19 sequelae was similarly elevated in responders with respiratory problems  
110 as well as heart disease, over and above the risk conferred by the COVID-19 severity itself.  
111 While respiratory and other chronic conditions are associated with toxic exposures during the  
112 9/11 disaster, some of the individual differences in post-exposure outcomes in 9/11 responders  
113 can be attributed to genetic vulnerabilities [16, 17].

114 Relatively little work describing genetic risk to COVID-19 severity has been conducted in  
115 community individuals with a full range of symptom severity. The associations between PRS and  
116 a common long-term outcome of post-acute COVID-19 also remain unknown. Thus, building on  
117 our previous work in the large sample of WTC responders who were infected with SARS-CoV-  
118 2, we investigated whether polygenic vulnerabilities to COVID-19 hospitalization, as well as to  
119 asthma, related allergic diseases, coronary artery disease, and type II diabetes, were associated  
120 with COVID-19 severity and post-acute COVID-19 symptoms, after adjusting for established  
121 risk factors. We investigated genetic associations with a full range of COVID-19 symptoms, as  
122 well as genetic risk for the severe COVID-19, which has the highest clinical relevance as it  
123 includes hospitalized cases. Based on previous findings, we hypothesized that PRS for COVID-  
124 19 hospitalization would be significantly associated with COVID-19 severity across a range of  
125 symptoms, and would help identify the most severe COVID-19 group. We tentatively  
126 hypothesized that PRS for asthma, allergic disease, coronary artery disease, and type II diabetes  
127 would be associated with worse COVID-19 severity outcomes and that the polygenic  
128 associations would extend to development of post-acute COVID-19 sequelae. We

## 129 **Methods**

### 130 **Participants and Procedure**

131 Participants were 983 WTC responders enrolled in a prospective cohort called the WTC Health  
132 Program which was established in 2002 and independently monitors the health of more than  
133 13,000 WTC first responders living on Long Island, NY, USA [18]. The analytic sample  
134 comprised of all genotyped participants from an established cohort of responders with the first  
135 instance of SARS-CoV-2 infection before January 2022, with the median infection date of  
136 December 2020 [2]. The mean age of the analytic sample at infection was 56.06,  $SD=7.37$ ,  
137  $range= 39.79-89.04$ , 93.4% of the sample was male, and 82.3% had European ancestry. The  
138 analytic sample did not differ significantly from the total cohort of responders with SARS-CoV-  
139 2 infection ( $N=1,280$ ) on demographic and symptom variables (all p-values for independent  
140 sample t-tests and chi-square tests  $>0.05$ ).

141 The analytic sample included responders with a verified history of a positive polymerase chain  
142 reaction, antigenic, or antibody test for SARS-CoV-2 or positivity for antibodies to SARS-CoV-  
143 2 nucleocapsid protein according to medical or laboratory records ( $N=587$ ), as well as  
144 responders who reported a positive laboratory test for SARS-CoV-2, but for whom documented  
145 proof of the test results was not available ( $N=396$ ). The unverified cases did not differ  
146 significantly from verified cases on all study variables, except for lower COVID-19 severity  
147 ( $t(df)=2.30 (847.60)$ ,  $p=.02$ ,  $d=.15$ ). Verifiable hospitalization records at local hospitals increased  
148 the likelihood of objectively verifying the most severe responders. Analyses adjusted for  
149 verification status. All cases represent a first instance of SARS-CoV-2 infection.

150 Clinical information on initial and residual COVID-19 symptoms was collected irrespective of  
151 verification status through in-person questionnaires, surveys sent via email and text, electronic  
152 medical records obtained with the release of health information forms, and follow-up calls.  
153 Symptoms of COVID-19 in this study included respiratory symptoms (i.e., shortness of breath,  
154 chest pain, sore throat, congestion/runny nose, and wheezing), systemic symptoms (i.e., fever,  
155 fatigue, headache, chills, and weight loss), gastrointestinal symptoms (i.e., nausea, vomiting, and  
156 diarrhea), musculoskeletal symptoms (i.e., joint and muscle pain), central nervous system  
157 symptoms (i.e., dizziness, vertigo, loss of smell/taste, and brain fog), and psychiatric symptoms  
158 (i.e., anxiety, depression, and post-traumatic stress disorder [PTSD]).

159 Blood samples for genotyping were drawn at the WTC Health Program clinic as a routine part of  
160 the monitoring examination from January 2012 to January 2019. The study was approved by the  
161 Institutional Reviewer Board of Stony Brook University, and all participants provided written  
162 informed consent. For more information on the study design, see Lhuillier, Yang [2].

## 163 **Measures**

### 164 **COVID-19 severity**

165 Participants in the analytic sample were categorized into four severity groups according to their  
166 symptoms: asymptomatic ( $N=92$ , 9.4%), mild ( $N=378$ , 38.5%), moderate ( $N=408$ , 41.5%), and  
167 severe ( $N=75$ , 7.6%). This categorization was based on the NIH COVID-19 clinical spectrum  
168 updated October 2021 (National Institutes of Health, 2021). The asymptomatic category  
169 consisted of responders who reported a positive SARS-CoV-2 virologic test result without any  
170 symptoms associated with COVID-19. The mild category included responders with at least one  
171 symptom associated with COVID-19 but no shortness of breath or difficulty breathing. Moderate



172 cases were in responders who reported shortness of breath and/or diagnosis of lower respiratory  
173 disease (pneumonia/bronchitis) during clinical assessment or imaging. These responders  
174 maintained oxygen saturation ( $SpO_2$ ) $\geq$ 94% on room air at sea level. Mild and moderate cases  
175 were medically managed primarily at home, even if they initially visited a healthcare facility for  
176 medical treatment and/or testing. Severe cases included responders with  $SpO_2$  $<$ 93% on room air,  
177 respiratory rate  $>$ 30 breaths/min, heart rate greater than 100 beats per minute, acute respiratory  
178 distress syndrome, septic shock, cardiac dysfunction, or an exaggerated inflammatory response  
179 in addition to pulmonary disease, or severe illness causing cardiac, hepatic, renal, central nervous  
180 system, or thrombotic disease during COVID-19. Responders were also categorized as severe if  
181 they were admitted to the hospital, or received intensive care or mechanical ventilation, or if they  
182 eventually died from COVID-19.

183 Two complimentary analytic variables were created: an ordinal COVID-19 severity variable on  
184 1-4 scale corresponding to asymptomatic, mild, moderate, and severe symptoms, and a binary  
185 COVID-19 severe category variable, with asymptomatic, mild, and moderate patients in one  
186 category, and severe patients in the second category.

### 187 **Post-acute COVID-19 symptoms**

188 Residual symptoms were defined as any COVID-19-related symptoms that lasted at least 4  
189 weeks after symptom onset (Centers for Disease Control and Prevention, 2021b). Residual  
190 symptoms included respiratory problems (e.g., dyspnea, chest discomfort, cough, and fatigue),  
191 CNS symptoms (e.g., loss or reduction of smell/taste, mental fog, dizziness, and vertigo), and  
192 musculoskeletal complaints. In the analytic sample, N=306 (31.1%) participants reported at least

193 one residual COVID-19 symptom. A binary analytic variable was created to compare  
194 participants with and without at least one residual symptoms.

## 195 **Covariates**

196 Electronic medical records updated on January 1, 2020, were used to obtain date of birth to  
197 calculate age at infection, obstructive airway disease and upper respiratory disease diagnoses,  
198 lifetime posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) diagnoses,  
199 and the most recent available measure of body mass index (BMI). Obstructive airway disease  
200 category includes diagnoses of asthma and bronchitis, upper respiratory disease includes chronic  
201 rhinitis and chronic sinusitis [18]. Respiratory diagnoses were determined based on systemic  
202 examination by a physician or nurse practitioner and included repeated pulmonary function tests,  
203 physical examination, and medical history. BMI scores were analyzed as continuous variable to  
204 maximize statistical power [19, 20]. Genetic data were used to obtain sex and ancestry  
205 information.

## 206 **Genetic data processing and polygenic risk scores (PRS)**

207 Genotyping of blood samples was performed at the Genomics Shared Resource at Roswell Park  
208 Cancer Institute, using the Infinium Global Screening Array (Illumina, San Diego, CA, USA),  
209 according to manufacturer protocols. Genotypes were imputed on the Michigan Imputation  
210 Server pipeline v1.2.4, using the Haplotype Reference Consortium reference panel [21]. Before  
211 imputation, the genotypes were filtered for ambiguous strand orientation, missingness rate >5%  
212 (by marker exclusion, then by individual), Hardy-Weinberg equilibrium violation ( $p < 10^{-6}$ ), and  
213 sex mismatch. After imputation, the single-nucleotide polymorphisms (SNPs) were excluded for  
214 imputation  $R^2 < 0.5$  and the average call rate below 90%. Genotype imputation was performed on

215 552,230 SNPs, resulting in 25,514,638 SNPs after quality control, which were used for matching  
216 to discovery GWAS variants for the final polygenic risk scoring.

217  
218 PRS were created using PRSice 2.0 [22]. PRS were created by aggregating genetic variants that  
219 emerged from the GWAS of the phenotype of interest, i.e. the GWAS discovery sample. Our  
220 primary analysis used a complete list of SNPs after clumping, and their corresponding weights  
221 from GWAS discovery samples (P-value threshold=1) to incorporate more of the genome [23].  
222 All analyses adjusted for the first ten genetic ancestry principal components (PCs). Primary  
223 analyses were conducted on participants of European ancestry due to the discovery GWAS being  
224 European; however, sensitivity analyses in the entire sample are also reported in the  
225 Supplementary Materials.

226 PRS for asthma and allergic disease were based on two GWAS conducted on participants of  
227 European ancestry from the UK Biobank [24]. The asthma GWAS was conducted in 90,853  
228 individuals, 14,085 physician-diagnosed asthma cases, and 76,768 controls without asthma or  
229 allergic diseases. Asthma is heterogeneous phenotype and cases with allergic, non-allergic,  
230 mixed, and other forms of asthma were included in GWAS. The allergic disease GWAS was  
231 conducted in 102,453 individuals, 25,685 with doctor-diagnosed hay fever, allergic rhinitis,  
232 eczema, or allergic asthma cases, and 76,768 controls without asthma or allergic disease.

233 The coronary artery disease PRS was based on a GWAS meta-analysis conducted in 122,733  
234 coronary artery disease cases and 424,528 controls from the UK Biobank and the  
235 CARDIoGRAMplusC4D Consortium [25]. Cases included patients with coronary artery disease  
236 diagnosis or treatment indicated in their electronic medical record or self-reported heart  
237 attack/myocardial infarction, coronary angioplasty, or heart bypass. The control group excluded

238 participants who reported that their mother, father, or sibling suffered from heart disease. The  
239 type II diabetes PRS was based on a GWAS meta-analysis in 62,892 type II diabetes cases and  
240 596,424 controls of European ancestry [26].

241 PRS for COVID-19 severity were based on summary statistics from two GWAS meta-analyses  
242 conducted by the COVID-19 Host Genetics Initiative [9] release 6, dated June 15, 2021. This  
243 initiative is an international collaboration spanning 61 studies from 24 countries. The first  
244 GWAS was performed in 2,085,803 individuals, contrasting 24,274 patients hospitalized due to  
245 COVID-19 with 2,061,529 population controls presumed to be COVID-19 negative (COVID-  
246 PRS hospitalized vs. population). The second GWAS was conducted in 87,671 patients with  
247 COVID-19, contrasting 14,480 hospitalized patients with 73,191 non-hospitalized patients  
248 (COVID-PRS hospitalized vs. not-hospitalized).

## 249 **Analytic approach**

250 Linear regression was used to test whether PRS is associated with ordinal COVID-19 severity.  
251 Logistic regression was used to test whether PRS is associated with the severe COVID-19  
252 category classification (severe vs. moderate/mild/asymptomatic), and the presence of post-acute  
253 COVID-19 symptoms. Continuous variables were standardized prior to analysis by transforming  
254 them to Z scores with a mean of zero and standard deviation of one. Models were adjusted for  
255 the first ten principal components of the population structure, COVID-19 verification status, age,  
256 and sex. Models testing asthma and allergic disease PRS were further adjusted for obstructive  
257 airway disease and upper respiratory disease diagnoses to ensure that associations do not merely  
258 reflect respiratory illness status. A supplementary analysis further adjusting for PTSD and MDD  
259 diagnoses was conducted for asthma PRS, to test the potential role of mental health in the

260 associations. Likewise, models testing PRS for coronary artery disease and type II diabetes  
261 further adjusted for BMI. Models testing associations with residual symptoms additionally  
262 adjusted for COVID-19 severity. Separate models were conducted for each PRS. The primary  
263 analyses were conducted in participants of European ancestry. Given that COVID-19 GWAS  
264 were completed using multi-ancestry participants, for sensitivity testing and inclusivity results  
265 are also reported for participants of all ancestries in Supplementary Materials. All analyses used  
266 nominal p-value threshold  $<.05$  and were conducted in SPSS version 28 and R version 4.1.0.

## 267 **Role of the funding source**

268 The funders had no role in the design of the study, in the collection, analyses, or interpretation of  
269 data, in the writing of the manuscript, or in the decision to publish the results.

## 270 **Results**

271 Descriptive statistics for the European ancestry sample are reported in Table 1. Many responders  
272 ( $N=57$ , 7.0%) had severe COVID-19. In total, 247 (30.4%) responders reported at least one  
273 residual COVID-19 symptom. Correlations between PRS are reported in Supplementary Table  
274 S1.

275

276 **Table 1 – Descriptive statistics for participants of European ancestry.**

277

N total	813
N male (%)	772 (95.0%)
Mean age at infection (SD), range	56.06 (7.37), 39.79-89.04
N OAD diagnosis (%)	312 (38.4%)
N URD diagnosis (%)	525 (64.6%)
N PTSD and/or MDD diagnosis (%)	124 (15.3%)
Mean BMI (SD), range	31.34 (5.08), 19.48-62.18
N COVID-19 severity (%)	
Asymptomatic	78 (9.6%)
Mild	320 (39.4%)
Moderate	332 (40.8%)
Severe	57 (7.0%)
Missing	26 (3.2%)
N any residual symptoms	247 (30.4%)

278

279 *Notes:*

280 OAD – Obstructive airway disease; URD – upper respiratory disease; PTSD-Posttraumatic stress

281 disorder, MDD – Major depressive disorder, BMI – body mass index; COVID-19 – coronavirus

282 disease 2019; SD - standard deviation.

283

284

285 The PRS for asthma was significantly associated with COVID-19 severity in the European  
286 ancestry subsample ( $\beta=.09$ ,  $p=.01$ ), adjusting for co-occurring obstructive airway disease  
287 diagnoses and upper respiratory disease diagnoses, Table 2. Likewise, the PRS for asthma was  
288 associated with COVID-19 severe category ( $OR=1.61$ , [1.17-2.21]). Allergic disease PRS  
289 showed a similar pattern, significantly associating the COVID-19 severe category ( $OR=1.97$ ,  
290 [1.26-3.07]). Associations with residual COVID-19 symptoms were not significant. There were  
291 no significant associations between coronary artery disease or type II diabetes PRS, and COVID-  
292 19 phenotypes (Table 3). The COVID-19 PRS based on the GWAS contrasting hospitalized  
293 cases vs. controls was significantly associated with the COVID-19 severe category in sample  
294 with European ancestry ( $OR=1.35$ , [1.01-1.82]), Table 4. Conversely, the COVID-19 PRS based  
295 on the GWAS contrasting hospitalized cases vs. non-hospitalized cases did not reach  
296 significance in the European ancestry subsample. Moreover, none of the COVID-19 PRS were  
297 associated with the full range of COVID-19 severity, nor the presence of any residual symptoms.  
298

299 **Table 2– Associations between allergic disease and asthma PRS and COVID-19 severity**  
 300 **and residual symptoms in participants of European ancestry.**

301

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: Asthma	$\beta=.09, p=.01$	<b>OR=1.61</b> (CI: 1.17-2.21), $p<.01$	OR=1.07 (CI: .90-1.27), $p=.43$
PRS: Allergic disease	$\beta=.09, p=.06$	<b>OR=1.97</b> (CI: 1.26-3.07), $p<.01$	OR=.89 (CI: .70-1.13), $p=.34$

302

303 *Notes:*

304 OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19:  
 305 coronavirus disease 2019. All models are adjusted for the first ten principal components of the  
 306 population structure, verification status, age at infection, sex, obstructive airway disease  
 307 diagnosis, upper respiratory disease diagnosis. Models with residual symptoms as a dependent  
 308 variable were additionally adjusted for COVID-19 severity. Associations between asthma PRS  
 309 and COVID-19 outcomes were not affected by lifetime PTSD and MDD diagnoses, see  
 310 Supplementary Table S6.

311

312



313 **Table 3 – Associations between coronary artery disease and type II diabetes PRS and**  
314 **COVID-19 severity and residual symptoms in participants of European ancestry.**

315

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: Coronary artery disease	$\beta=.05, p=.21$	$OR=1.06$ (CI: .70-1.60), $p=.79$	$OR=1.22$ (CI: .97-1.53), $p=.09$
PRS: Type II diabetes	$\beta=.04, p=.32$	$OR=1.42$ (CI: .80-2.53), $p=.23$	$OR=.71$ (CI: .50-1.01), $p=.05$

316

317 *Notes:*

318 OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19:  
319 coronavirus disease 2019. All models are adjusted for the first ten principal components of the  
320 population structure, verification status, age at infection, sex, and BMI. Models with residual  
321 symptoms as a dependent variable were additionally adjusted for COVID-19 severity.

322

323

324 **Table 4 – Associations between COVID-19 PRS and COVID-19 severity and residual**  
 325 **symptoms in participants of European ancestry.**

326

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: COVID-19 hospitalized vs. controls	$\beta=.03, p=.40$	<b>OR=1.35</b> (CI: 1.01-1.82), $p=.04$	OR=1.11 (CI: .93-1.33), $p=.24$
PRS: COVID-19 hospitalized vs. not-hospitalized	$\beta=.05, p=.23$	OR=1.27 (CI: .95-1.69), $p=.12$	OR=1.08 (CI:.90-1.29), $p=.41$

327

328 *Notes:*

329 OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19:

330 coronavirus disease 2019. All models are adjusted for the first ten principal components of the

331 population structure, verification status, age at infection, and sex. Models with residual

332 symptoms as a dependent variable were additionally adjusted for COVID-19 severity.

333

334

335

336

## 337 **Sensitivity analyses**

338 Descriptive statistics for total sample with participants of all ancestries are reported in  
339 Supplementary Table S2. In the total sample, adjusting for respiratory disease diagnoses, the  
340 PRS for asthma was significantly associated with COVID-19 severity ( $\beta=.08$ ,  $p=.01$ ) and  
341 COVID-19 severe category ( $OR=1.53$ , [1.15-2.03]), and the allergic disease PRS was associated  
342 with the COVID-19 severe category ( $OR=1.86$ , [1.25-2.77]), Supplementary Table S3. There  
343 were no significant associations between coronary artery disease or type II diabetes PRS, and  
344 COVID-19 phenotypes, Supplementary Table S4. The COVID-19 PRS based on the GWAS  
345 contrasting hospitalized cases vs. controls was significantly associated with the COVID-19  
346 severe category in the whole sample ( $OR=1.42$ , [1.11-1.82]), Supplementary Table S5. Likewise,  
347 the COVID-19 PRS based on the GWAS contrasting hospitalized cases vs. non-hospitalized  
348 cases was also significantly associated with COVID-19 severe category in the total sample  
349 ( $OR=1.33$ , [1.04-1.69]). Accounting for PTSD and MDD diagnoses did not alter associations  
350 between asthma PRS and COVID-19 outcomes, see Supplementary Table S6.

## 351 **Discussion**

352 The current study reports associations between recently developed polygenic biomarkers and  
353 COVID-19 severity in a community-based population of responders to the WTC disaster who  
354 had COVID-19. We found that the PRS for asthma, allergic diseases, and COVID-19 severity  
355 were elevated in the severe COVID-19 category responders.. Asthma PRS was additionally  
356 associated with COVID-19 symptomatology across the full spectrum of COVID-19 severity. No  
357 significant associations were observed for PRS for coronary artery disease and type II diabetes.  
358 Moreover, PRS were not associated with post-acute COVID-19 sequelae. These findings add to

359 the growing body of evidence to suggest that existing polygenetic profiles could be informative  
360 about the risk for severe COVID-19 presentation, despite the small effect sizes.

361 The current study is the first to report significant associations between asthma PRS and allergic  
362 disease PRS, and COVID-19 severity. A previous study in the UK Biobank found no association  
363 between asthma PRS and severe COVID-19 [14]. However, the direction of association was  
364 positive, and asthma diagnosis was significantly associated with COVID-19 severity ( $OR=1.39$ ),  
365 in line with epidemiological and clinical evidence [7]. In contrast to Zhu, Hasegawa [14], in our  
366 subsample with European ancestry, the PRS for asthma was associated with a 1.61-fold increase  
367 in the odds of classification into the most severe COVID-19 category, as well as with the full  
368 range of COVID-19 symptom severity, independently of respiratory diagnoses. Our focus on  
369 patients with a wide range of COVID-19 symptoms, in contrast with Zhu, Hasegawa [14] focus  
370 on hospitalized cases with severe COVID-19, might be a strength of the current study that  
371 explains different findings. Other potential explanations include demographic differences  
372 between the samples, data collection at different phases of the pandemic, and differences in  
373 sample sizes.

374

375 Allergic disease PRS based on the related GWAS of cases with doctor-diagnosed hay fever,  
376 allergic rhinitis, eczema, or allergic asthma doubled the odds of classification into the most  
377 severe COVID-19 category in participants of European ancestry ( $OR=1.97$ ), adjusting for  
378 demographic covariates and respiratory diagnoses. Taken together, these results are consistent  
379 with the evidence for the role of immune function genes implicated in COVID-19 severity [8]. It  
380 is possible that asthma and allergic sensitization contribute to the pathobiology of severe  
381 COVID-19, such as expression of the SARS-CoV-2 receptor ACE2 [27, 28], and that asthma and

382 allergic disease PRS capture these effects. Another possibility is that both asthma and atopic  
383 disease have a proclivity toward a TH2 immune response and thus may contribute to a TH1 or  
384 TH2 imbalance and a poorer outcome [29]. Finally, despite the substantial genetic correlation  
385 between asthma and mental health [30], responders' history of PTSD and MDD did not explain  
386 the association between asthma PRS and COVID-19 severity.

387  
388 Contrary to our hypotheses, PRS for coronary artery disease and type II diabetes were not  
389 associated with any COVID-19 outcomes. Cardiovascular and other obesity-related disorders  
390 have previously been highlighted as risk factors for severe COVID-19 presentation and residual  
391 symptoms [7, 31], including in our sample [2]. However, our findings suggest that genetic  
392 vulnerability to these conditions might not contribute prominently to COVID-19 severity. A  
393 study found a significant association between BMI PRS and higher risk of severe COVID-19  
394 outcomes such as hospitalization; however, the effect sizes were small ( $OR=1.14$ ) [32] and were  
395 below effect sizes the present study was powered to detect. Furthermore, the previous study did  
396 not find significant relationships between COVID-19 outcomes and PRS for BMI-adjusted  
397 waist-to-hip ratio and BMI-adjusted waist circumference, indicating an overall weak association  
398 between genetic vulnerability to high weight and COVID-19 severity, consistent with the current  
399 findings for PRS developed for coronary artery disease and type II diabetes.

400  
401 The PRS based on the largest GWAS to date comparing hospitalized COVID-19 cases to healthy  
402 controls [9] was significantly associated with a 1.35-fold increase in the odds of having had  
403 severe COVID-19. This finding agrees with previous studies based on large cohorts such as the  
404 UK Biobank which found that COVID-19 PRS were associated with severe COVID-19

405 outcomes [10-12]. For example, Nakanishi, Pigazzini [10] reported that COVID-19 PRS  
406 predicted death or severe respiratory failure (OR=1.70). Similarly, Horowitz, Kosmicki [11]  
407 reported that a PRS based on the top six SNPs associated with COVID-19 predicted a 1.38-fold  
408 increased risk of hospitalization and a 1.58-fold increased risk of severe disease in European  
409 ancestry participants, with results replicated in other ancestries. Importantly, COVID-19 severity  
410 PRS were not associated with the full spectrum of COVID-19 symptoms in our population and  
411 did not associate with residual post-acute COVID-19 syndrome. This finding adds novel  
412 evidence that the COVID-19 PRS specifically captures genetic vulnerability to a severe response  
413 to SARS-CoV-2 infection.

414

## 415 **Strengths and Limitations**

416 The strengths of the current study include a large sample with well-characterized COVID-19  
417 symptomatology, follow-up information on post-acute COVID-19 sequelae, and application of  
418 PRS based on the largest discovery samples available for each disease. Nonetheless, we also note  
419 several limitations. First, although we demonstrated that genotyped patients did not differ  
420 significantly from non-genotyped patients, the specific inclusion and exclusion criteria might  
421 result in selection bias, contributing to the broader non-representativeness of the WTC cohort to  
422 the general population. The proportion of individuals with ancestry admixture in the WTC  
423 cohort is too small to allow genetic analyses in non-Northern European ancestries. Nonetheless,  
424 for transparency, we opted to report analyses in the total sample as well as the European ancestry  
425 subsample, and results are notably similar. In either sample, we were underpowered to detect  
426 very small associations. Relatedly, the WTC responder population is primarily male, and the  
427 number of females was insufficient to explore sex differences. Moreover, we were underpowered

428 to stratify the sample by age, respiratory illness, or other characteristics related to COVID-19  
429 severity. We have adjusted for these covariates in our analyses, but acknowledge that the  
430 findings arising from the current study may not generalize to other populations.

431 Second, some participants were included based on infection information that was not  
432 independently verified by the study team. However, these participants reported testing positive  
433 for SARS-CoV-2 through one of the available testing methods and did not differ from verified  
434 participants on any characteristics except COVID-19 severity, which is due to verified records  
435 being available for hospitalized responders, suggesting that misclassification was likely to be  
436 minimal. The COVID-19 verification status was included as a covariate in all analyses. Third,  
437 different viral strains emerged and vaccination status changed over the course of this study.  
438 These factors can affect infection susceptibility and COVID-19 disease severity. For example,  
439 COVID-19 vaccines are very effective in lowering infection and disease severity [33, 34], which  
440 in turn could decrease the role of host genetics in COVID-19 outcomes, attenuating observed  
441 PRS associations. Moreover, in vaccinated individuals, PRS associations with COVID-19  
442 severity could instead reflect vulnerability to vaccine breakthroughs. We did not have sufficient  
443 data to investigate these issues, which likely have contrasting effects on our results, and limit  
444 their comparability to studies conducted at different points in the pandemic. Future studies of  
445 PRS are needed to model complex interactions between these factors.

446 Fifth, the current study used asthma PRS based on a GWAS of a broadly defined asthma.  
447 However, asthma is a complex and heterogeneous condition, with allergic and non-allergic  
448 asthmas demonstrating partially different genetic etiologies [24, 35, 36]. Accordingly, PRS for  
449 specific asthma subtypes based on allergy and age-at-onset have been shown to differentially  
450 associate with outcomes such as BMI [37]. Thus, future work should replicate and clarify

451 whether observed associations between asthma PRS and COVID-19 severity differ across  
452 asthma subtypes.

## 453 **Conclusions**

454 The current translational study found that PRS for asthma, allergic disease, and COVID-19  
455 hospitalization were associated with an increased risk for severe COVID-19 presentation among  
456 community-based individuals infected with SARS-CoV-2. Asthma PRS was also associated with  
457 higher COVID-19 severity across the full range of COVID-19 symptoms. The current effect  
458 sizes were small, but with additional research, known genetic vulnerability factors might help to  
459 identify individuals at an increased risk for a severe course of COVID-19 disease.

460

## 461 **Acknowledgements**

462 We thank participants for their commitment to the project

## 463 **Funding Source**

464 The study was funded by CDC/NIOSH awards U01OH012275 to Drs. Luft and Morozova, and  
465 U01OH011864 to Drs. Waszczuk and Kotov. Additional support was provided by National  
466 Institute of Health awards R01MH123619 and R01MH123489 to Drs. Docherty and Shabalin.  
467 We would like to acknowledge ongoing funding to monitor World Trade Center responders as  
468 part of the WTC Health and Wellness Program (CDC 200-2011-39361). The findings and



469 conclusions in this article are those of the authors and do not represent the official position of  
470 CDC.

## 471 **Conflict of Interest Statement**

472 The authors declare no conflict of interest. The funders had no role in the design of the study; in  
473 the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the  
474 decision to publish the results.

## 475 **Data Availability Statement**

476 Data file is available at synapse.org (<https://www.synapse.org/#!/Synapse:syn44590167>,  
477 doi:10.7303/syn44590167)

478

## 479 **References**

- 480 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in  
481 real time. *The Lancet infectious diseases*. 2020;20(5):533-4.
- 482 2. Lhuillier E, Yang Y, Morozova O, Clouston SA, Yang X, Waszczuk MA, et al. The  
483 Impact of World Trade Center Related Medical Conditions on the Severity of COVID-19  
484 Disease and Its Long-Term Sequelae. *International Journal of Environmental Research and  
485 Public Health*. 2022;19(12):6963.
- 486 3. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-  
487 acute COVID-19 syndrome. *Nature medicine*. 2021;27(4):601-15.
- 488 4. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and  
489 long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. *JAMA  
490 network open*. 2021;4(10):e2128568-e.
- 491 5. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors  
492 associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430-6.
- 493 6. Ebinger JE, Achamallah N, Ji H, Claggett BL, Sun N, Botting P, et al. Pre-existing traits  
494 associated with Covid-19 illness severity. *PLoS One*. 2020;15(7):e0236240.
- 495 7. Gao Yd, Ding M, Dong X, Zhang Jj, Kursat Azkur A, Azkur D, et al. Risk factors for  
496 severe and critically ill COVID-19 patients: a review. *Allergy*. 2021;76(2):428-55.
- 497 8. Niemi ME, Daly MJ, Ganna A. The human genetic epidemiology of COVID-19. *Nature  
498 Reviews Genetics*. 2022:1-14.
- 499 9. COVID-19 Host Genetics Initiative. The COVID-19 host genetics initiative, a global  
500 initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-  
501 CoV-2 virus pandemic. *European Journal of Human Genetics*. 2020;28(6):715.

- 502 10. Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, et  
503 al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity  
504 and mortality. *The Journal of clinical investigation*. 2021;131(23).
- 505 11. Horowitz JE, Kosmicki JA, Damask A, Sharma D, Roberts GH, Justice AE, et al.  
506 Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and  
507 yields risk scores associated with severe disease. *Nature genetics*. 2022;54(4):382-92.
- 508 12. Huang Q-M, Zhang P-D, Li Z-H, Zhou J-M, Liu D, Zhang X-R, et al. Genetic risk and  
509 chronic obstructive pulmonary disease independently predict the risk of incident severe COVID-  
510 19. *Annals of the American Thoracic Society*. 2022;19(1):58-65.
- 511 13. Crossfield SS, Chaddock NJ, Iles MM, Pujades-Rodriguez M, Morgan AW. Interplay  
512 between demographic, clinical and polygenic risk factors for severe COVID-19. *International  
513 Journal of Epidemiology*. 2022.
- 514 14. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of asthma and  
515 its genetic predisposition with the risk of severe COVID-19. *Journal of Allergy and Clinical  
516 Immunology*. 2020;146(2):327-9. e4.
- 517 15. Morozova O, Clouston SA, Valentine J, Newman A, Carr M, Luft BJ. COVID-19  
518 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January–August  
519 2020: A cohort of World Trade Center responders. *PLoS One*. 2021;16(7):e0254713.
- 520 16. Waszczuk MA, Docherty AR, Shabalin AA, Miao J, Yang X, Kuan P-F, et al. Polygenic  
521 prediction of PTSD trajectories in 9/11 responders. *Psychological Medicine*. 2020:1-9.
- 522 17. Huckins LM, Johnson JS, Cancelmo L, Diab O, Schaffer J, Cahn L, et al. Polygenic  
523 regulation of PTSD severity and outcomes among World Trade Center responders. *medRxiv*.  
524 2021:2020.12. 06.20244772.

- 525 18. Dasaro CR, Holden WL, Berman KD, Crane MA, Kaplan JR, Lucchini RG, et al. Cohort  
526 Profile: World Trade Center Health Program General Responder Cohort. *International Journal of*  
527 *Epidemiology*. 2015.
- 528 19. Cohen J. The cost of dichotomization. *Applied psychological measurement*.  
529 1983;7(3):249-53.
- 530 20. MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization  
531 of quantitative variables. *Psychological methods*. 2002;7(1):19.
- 532 21. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A  
533 reference panel of 64,976 haplotypes for genotype imputation. *Nature genetics*.  
534 2016;48(10):1279.
- 535 22. Euesden J, Lewis CM, O'Reilly PF. PRSice: polygenic risk score software.  
536 *Bioinformatics*. 2015;31(9):1466-8.
- 537 23. Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM. Research  
538 review: polygenic methods and their application to psychiatric traits. *Journal of Child*  
539 *Psychology and Psychiatry*. 2014;55(10):1068-87.
- 540 24. Zhu Z, Lee PH, Chaffin MD, Chung W, Loh P-R, Lu Q, et al. A genome-wide cross-trait  
541 analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic  
542 diseases. *Nature genetics*. 2018;50(6):857-64.
- 543 25. Van Der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded  
544 view on the genetic architecture of coronary artery disease. *Circulation research*.  
545 2018;122(3):433-43.

- 546 26. Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide association  
547 analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.  
548 Nature communications. 2018;9(1):1-14.
- 549 27. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al.  
550 Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2.  
551 Journal of Allergy and Clinical Immunology. 2020;146(1):203-6. e3.
- 552 28. Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, et al. Type 2  
553 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway  
554 epithelium. Nature communications. 2020;11(1):1-18.
- 555 29. Gil-Etayo FJ, Suárez-Fernández P, Cabrera-Marante O, Arroyo D, Garcinuño S, Naranjo  
556 L, et al. T-helper cell subset response is a determining factor in COVID-19 progression.  
557 Frontiers in cellular and infection microbiology. 2021;11:624483.
- 558 30. Zhu Z, Zhu X, Liu C-L, Shi H, Shen S, Yang Y, et al. Shared genetics of asthma and  
559 mental health disorders: a large-scale genome-wide cross-trait analysis. Eur Respir J. 2019;54(6).
- 560 31. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al.  
561 Association of obesity with disease severity among patients with coronavirus disease 2019.  
562 Obesity. 2020;28(7):1200-4.
- 563 32. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and  
564 its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort  
565 data. Metabolism. 2020;112:154345.
- 566 33. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of  
567 COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252-60.

- 568 34. Mohammed I, Nauman A, Paul P, Ganesan S, Chen K-H, Jalil SMS, et al. The efficacy  
569 and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and  
570 mortality: A systematic review. *Hum Vaccin Immunother.* 2022;18(1):2027160.
- 571 35. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective.  
572 *Immunological reviews.* 2011;242(1):10-30.
- 573 36. Zhu Z, Hasegawa K, Camargo Jr CA, Liang L. Investigating asthma heterogeneity  
574 through shared and distinct genetics: Insights from genome-wide cross-trait analysis. *Journal of*  
575 *Allergy and Clinical Immunology.* 2021;147(3):796-807.
- 576 37. Zhu Z, Guo Y, Shi H, Liu C-L, Panganiban RA, Chung W, et al. Shared genetic and  
577 experimental links between obesity-related traits and asthma subtypes in UK Biobank. *Journal of*  
578 *Allergy and Clinical Immunology.* 2020;145(2):537-49.

579

580

## 581 **Supporting Information**

582 **Table S1. Associations among PRS used in the study**

583 **Table S2. Descriptive statistics for participants of all ancestries**

584 **Table S3. Associations between allergic disease and asthma PRS and COVID-19 severity**  
585 **and residual symptoms in participants of all ancestries**

586 **Table S4. Associations between coronary artery disease and type II diabetes PRS and**  
587 **COVID-19 severity and residual symptoms in participants of all ancestries**

588 **Table S5. Associations between COVID-19 PRS and COVID-19 severity and residual**  
589 **symptoms in participants of all ancestries**

590 **Table S6. Mental health and associations between COVID-19 outcomes and PRS for**  
591 **asthma in European ancestry participants**